PDL BioPharma, Inc. (NASDAQ:PDLI) went up by 3.68% from its latest closing price compared to the recent 1-year high of $3.78. The company’s stock price has collected 0.60% of gains in the last five trading sessions. Press Release reported on 09/10/20 that PDL BioPharma to Complete Spin-Off of LENSAR, Inc. on October 1, 2020
Is It Worth Investing in PDL BioPharma, Inc. (NASDAQ :PDLI) Right Now?
PDL BioPharma, Inc. (NASDAQ:PDLI) scored a price-to-earnings ratio above its average ratio, recording 968.86 x from its present earnings ratio. Plus, the 36-month beta value for PDLI is at 0.94. Opinions of the stock are interesting as 0 analysts out of 1 who provided ratings for PDL BioPharma, Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $3.00, which is -$3.38 below the current price. PDLI currently public float of 110.01M and currently shorts hold a 11.71% ratio of that float. Today, the average trading volume of PDLI was 1.18M shares.
PDLI’s Market Performance
PDLI stocks went up by 0.60% for the week, with a monthly jump of 3.05% and a quarterly performance of 4.32%, while its annual performance rate touched 81.77%. The volatility ratio for the week stands at 3.45% while the volatility levels for the past 30 days are set at 4.11% for PDL BioPharma, Inc.. The simple moving average for the period of the last 20 days is -0.14% for PDLI stocks with a simple moving average of 17.23% for the last 200 days.
Analysts’ Opinion of PDLI
Many brokerage firms have already submitted their reports for PDLI stocks, with Piper Jaffray repeating the rating for PDLI by listing it as a “Overweight.” The predicted price for PDLI in the upcoming period, according to Piper Jaffray is $31 based on the research report published on December 22nd of the previous year 2016.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see PDLI reach a price target of $4, previously predicting the value of $5. The rating they have provided for PDLI stocks is “Sector Perform” according to the report published on February 23rd, 2016.
RBC Capital Mkts gave a rating of “Sector Perform” to PDLI, setting the target price at $5 in the report published on February 2nd of the previous year.
PDLI Trading at 5.98% from the 50-Day Moving Average
After a stumble in the market that brought PDLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.58% of loss for the given period.
Volatility was left at 4.11%, however, over the last 30 days, the volatility rate increased by 3.45%, as shares surge +1.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.15% upper at present.
During the last 5 trading sessions, PDLI rose by +0.60%, which changed the moving average for the period of 200-days by +12.29% in comparison to the 20-day moving average, which settled at $3.39. In addition, PDL BioPharma, Inc. saw 25.47% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for PDLI
Current profitability levels for the company are sitting at:
- -121.55 for the present operating margin
- -9.44 for the gross margin
The net margin for PDL BioPharma, Inc. stands at -128.59. The total capital return value is set at -9.01, while invested capital returns managed to touch -9.54.
Based on PDL BioPharma, Inc. (PDLI), the company’s capital structure generated 4.88 points at debt to equity in total, while total debt to capital is 4.65. Total debt to assets is 4.04, with long-term debt to equity ratio resting at -5.84. Finally, the long-term debt to capital ratio is 4.72.
When we switch over and look at the enterprise to sales, we see a ratio of 4.03, with the company’s debt to enterprise value settled at 0.13. The receivables turnover for the company is 0.70 and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.87.